Back
Esperion Therapeutics 10K Form
Sell
26
ESPR
Esperion Therapeutics
Last Price:
1.97
Seasonality Move:
-4.18%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2003-11-10 | 10Q | ESPR/Esperion Therapeutics Quarterly |
| 2003-10-28 | 10Q | ESPR/Esperion Therapeutics Quarterly |
| 2003-08-14 | 10Q | ESPR/Esperion Therapeutics Quarterly |
| 2003-03-26 | 10K | ESPR/Esperion Therapeutics Annual |
| 2002-03-19 | 10K | ESPR/Esperion Therapeutics Annual |
| 2002-03-14 | 10K | ESPR/Esperion Therapeutics Annual |
Receive ESPR News And Ratings
See the #1 stock for the next 7 days that we like better than ESPR
ESPR Financial Statistics
Sales & Book Value
| Annual Sales: | $116.33M |
|---|---|
| Cash Flow: | $-37.06M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $-3.85 |
| Price / Book: | 0 |
Profitability
| EPS (TTM): | -2.12000 |
|---|---|
| Net Income (TTM): | $-209.25M |
| Gross Margin: | $73.07M |
| Return on Equity: | 0% |
| Return on Assets: | -90.08% |
Esperion Therapeutics Earnings Forecast
Key Esperion Therapeutics Financial Ratios
- The Gross Profit Margin over the past 17 years for ESPR is 62.81%.
- The Selling, General & Administrative Expenses for ESPR have been equal to 122.51% of Gross Profit Margin.
- The Research & Development expenses have been 74.02% of Revenue.
- The Interest Expense is -28.18% of Operating Income.
- The Net Earning history of ESPR is -179.87% of Total Revenues.
- Per Share Earnings over the last 17 years have been positive in 6 years.
Esperion Therapeutics Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Pharmaceuticals |
| Sector: | Health Care |
| Current Symbol: | ESPR |
| CUSIP: | 29664W |
| Website: | esperion.com |
Debt
| Debt-to-Equity Ratio: | -0.57 |
|---|---|
| Current Ratio: | 1.29 |
| Quick Ratio: | 0.84 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 11.48 |
ESPR Technical Analysis vs Fundamental Analysis
Sell
26
Esperion Therapeutics (ESPR)
is a Sell
Is Esperion Therapeutics a Buy or a Sell?
-
Esperion Therapeutics stock is rated a Sell
The current Esperion Therapeutics [ESPR] share price is $2.13. The Score for ESPR is 26, which is 48% below its historic median score of 50, and infers higher risk than normal.